Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Comment

ASCO 2020: Overall survival benefit from secondary cytoreductive surgery, and results from SOLO-2 and FORWARD II for recurrent ovarian cancer

Close
Close
Close

Go Top